miR-18a treatment led to increasing percentages of F4/80+IFNγ+, F4/80+IL-12+, F4/80+CD80+, and decreasing percentages of F4/80+ transforming growth factor beta (TGFβ)+, F4/80+CD206+ and F4/80+ IL-10+ detected in the liver metastatic tumor bearing mice (Figure 2B). This evidence concerns the gene TGFB1 and metastatic neoplasm.